SCHEMBL4552085

SCHEMBL4552085

Cc1cc(-c2nc(-c3ccccc3)c(-c3ccccc3)[nH]2)ccc1C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.67
KMT2A Q03164 4/20 0.67
ALDH1A1 P00352 3/20 0.67
GLA P06280 3/20 0.67
GAA P10253 3/20 0.67
HPGD P15428 3/20 0.67
MEN1 O00255 3/20 0.67
POLB P06746 1/20 0.61
MAPT P10636 3/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2C19 P33261 1/20 0.59
GFER P55789 1/20 0.59
PTPN1 P18031 1/20 0.58
NOX1 Q9Y5S8 2/20 0.55
MAPK14 Q16539 3/20 0.55
CSNK1D P48730 1/20 0.55
CSNK1E P49674 1/20 0.55
RAF1 P04049 2/20 0.54
MPO P05164 1/20 0.54
MAPK13 O15264 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7989834 0.85 MAPK11 (0.71) KDM4EKMT2AALDH1A1HPGDMEN1
SCHEMBL4551698 0.82 KMT2A (0.57) KDM4EKMT2AALDH1A1GLAGAA
SCHEMBL4153691 0.81 TGFBR1 (0.74) KDM4EKMT2AALDH1A1GLAGAA
SCHEMBL2593317 0.80 KDM4E (0.91) KDM4EKMT2AALDH1A1GLAGAA
SCHEMBL29642733 0.80 KDM4E (1.00) KDM4EKMT2AALDH1A1GLAGAA
SCHEMBL12462140 0.79 MAPK14 (0.62) KDM4EKMT2AALDH1A1GLAGAA
SCHEMBL12152244 0.79 NOX1 (0.68) KDM4EKMT2AALDH1A1GLAGAA
SCHEMBL12311036 0.79 KDM4E (0.67) KDM4EKMT2AALDH1A1GLAGAA
SCHEMBL30979828 0.77 MAPK13 (0.60) KDM4EKMT2AALDH1A1GLAGAA
SCHEMBL30979849 0.77 MAPK13 (0.60) KDM4EKMT2AALDH1A1GLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof REDPOINT BIO CORPORATION 2007-11-08 US claimed
EP-2015638-A2 TRIARYL SUBSTITUTED IMIDAZOLE DERIVATIVES AND TASTE-INHIBITING USES THEREOF Redpoint Bio Corporation (US) 2009-01-21 EP disclosed
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof REDPOINT BIO CORPORATION 2007-11-08 US disclosed
WO-2007127479-A2 TRIARYL SUBSTITUTED IMIDAZOLE DERIVATIVES AND TASTE-INHIBITING USES THEREOF REDPOINT BIO CORPORATION (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof TAS1R3, TAS2R1, TAS1R1 KDM4E 3422/4885KMT2A 3144/4885ALDH1A1 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.